Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A study of PRS-344/S095012 (PD-L1x4-1BB bispecific antibody) in patients with solid tumors Ended

2023-510046-25-00 Soild Tumors 7 2021-09-02
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) Ended

2024-511728-15-00 Solid tumors 7 2021-08-26
A study of enfortumab vedotin given in the bladder for treatment of patients with non-muscle invasive bladder cancer (NMIBC). Ended

2023-503388-40-00 Non-muscle invasive bladder cancer 3 2021-08-24
This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors) Ended

2024-511503-41-00 Advanced or metastatic solid tumors 3 2021-08-13
Phase 2 First-Line ES-SCLC Platform Study Ended

2023-506538-56-00 First-line treatment of participants with extensive-sta 4 2021-08-12
A Phase 2 Study of ALX148 in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) Ended

2023-508340-22-00 metastatic or unresectable, recurrent HNSCC 4 2021-08-11
A Phase 2 study of ALX148 in Combination With Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma… Ended

2023-508342-17-00 metastatic or unresectable, recurrent HNSCC 4 2021-08-11
Study of REGN6569 and Cemiplimab in Adult Patients with Advanced Solid Tumor Malignancies Ended

2022-500868-36-00 Squamous Cell Carcinoma of Head and Neck 1 2021-08-11
A Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer Ended

2024-511158-36-00 Metastatic colorectal cancer 9 2021-08-05
A study to test different doses of BI 1823911 alone and combined with other medicines in people with different types of advanced cancer with… Ended

2024-512805-18-00 solid tumour harbouring G12C mutation 3 2021-08-03
Integrative analysis of the tumor microenvironment and optimization of the immunotherapy duration in non-small cell lung cancer patients. Ended

2023-509490-23-00 Patients with locally advanced or metastasic Non-Small 4 2021-08-03
A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participan… Ended

2024-512227-36-00 Advanced solid tumors 9 2021-07-28
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function Ended

2023-509915-10-00 Relapsed or Refractory Multiple Myeloma 3 2021-07-27
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM14 in Combination with Irinotecan in Pretreated Patients with S… Ended

2024-514890-24-00 Patients with Selected Advanced Solid Tumors 4 2021-07-23
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal … Ended

2022-501342-29-00 Esophageal Carcinoma 5 2021-07-21
A phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously tr… Ended

2024-514611-98-00 PIK3CA mutated HER2+ advanced or relapsed breast cancer 5 2021-07-20
A Phase 1b Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in Relapsed or Refractory B cell Non-Hodgkin Lymphoma and … Ended

2024-512689-32-00 Non-Hodgkin lymphoma and chronic lymphocytic leukemia 3 2021-07-15
Phase 2 Study of MK-1308A (Coformulated MK-1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular C… Ended

2023-505698-34-00 Hepatocellular carcinoma 4 2021-07-13
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Ended

2023-503387-16-00 Classical Hodgkin Lymphoma 4 2021-07-13
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Inavolisib in Combination with Paclit… Ended

2023-506745-33-00 Locally Advanced or Metastatic Solid Tumors 3 2021-07-12
Clinical trial to assess the safety and efficacy of AloCELYVIR in children, adolescent and young adults with diffuse intrinsic pointine glio… Ended

2022-502516-37-00 Newly diagnosed Diffuse Intrinsic Pointine Glioma (DIPG 3 2021-07-12
Tucatinib and trastuzumab in solid tumors with HER2 alterations Ended

2024-511481-37-00 Previously Treated, Locally-Advanced Unresectable or Me 4 2021-07-12
A Dose Finding Phase 1 Study of CC-96191 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia Ended

2022-500573-13-00 Relapsed or Refractory Acute Myeloid Leukemia 1 2021-07-06
CAIRE : COMBINING EPIGENETIC AND IMMUNE THERAPY TO BEAT CANCER Ended

2023-509501-72-00 Adult participants with metastatic or unresectable loca 4 2021-07-05